Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.52 |
| ▸ | ILK | Q13418 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | SCN4A | P35499 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | NCS1 | P62166 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 6/20 | 0.40 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31547354 | 1.00 | DYRK1A (0.52) | DYRK1AILKEPHX2SCN4AKDM4E | |
| SCHEMBL1747959 | 0.86 | EPHX2 (0.65) | DYRK1AEPHX2SCN4AKDM4EBACE1 | |
| SCHEMBL11845650 | 0.82 | TRPV1 (0.42) | DYRK1AILKTRPV1 | |
| SCHEMBL15708155 | 0.80 | DYRK1A (0.54) | DYRK1AILKEPHX2SCN4AKDM4E | |
| SCHEMBL30261092 | 0.79 | SCN4A (0.75) | DYRK1AILKEPHX2SCN4ABACE1 | |
| SCHEMBL777758 | 0.79 | DYRK1A (0.52) | DYRK1AILKEPHX2SCN4AKDM4E | |
| SCHEMBL9853857 | 0.79 | POLB (0.56) | DYRK1AILKEPHX2SCN4AALOX5 | |
| SCHEMBL4090777 | 0.79 | DYRK1A (0.52) | DYRK1AILKEPHX2SCN4AKDM4E | |
| SCHEMBL1913811 | 0.79 | SCN4A (0.75) | DYRK1AILKEPHX2SCN4ABACE1 | |
| SCHEMBL17153983 | 0.77 | ALOX5 (0.52) | DYRK1AILKEPHX2SCN4AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090589-A1 | HETEROCYCLIC HBS1L DEGRADERS | TANGO THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12600837-B2 | Rubber composition and crosslinked rubber molded product | SUMITOMO RUBBER INDUSTRIES, LTD. (JP) | 2026-04-14 | — | — | US | disclosed |
| CN-120261758-A | Preparation method of novel polymer and high-ion-conductivity lithium ion solid-state battery | 苏州浦昌新能源有限公司 | 2025-07-04 | — | — | CN | disclosed |
| US-12344690-B2 | Rubber composition and crosslinked rubber molded product | SUMITOMO RUBBER INDUSTRIES, LTD. (JP) | 2025-07-01 | — | — | US | disclosed |
| US-12275807-B2 | Rubber composition and crosslinked rubber molded product | SUMITOMO RUBBER INDUSTRIES, LTD. (JP) | 2025-04-15 | — | — | US | disclosed |
| US-20240132705-A1 | RUBBER COMPOSITION AND CROSSLINKED RUBBER MOLDED PRODUCT | SUMITOMO RUBBER INDUSTRIES, LTD. (JP) | 2024-04-25 | — | — | US | disclosed |
| CN-117843579-A | Benzo heterocycle coupled catechol derivative and preparation method and application thereof | 暨南大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-116926578-A | Method for synthesizing heteroaryl thiophenol | 新疆大学 | 2023-10-24 | — | — | CN | disclosed |
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO HEALTH, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO HEALTH, INC. | 2023-08-03 | — | — | US | disclosed |
| WO-1994006783-A1 | BENZOXAZOLE AND BENZOTHIAZOLE DERIVATIVES | ZENECA LIMITED (GB) | 1994-03-31 | — | — | WO | disclosed |
| US-5152929-A | Corrosion inhibitors for water systems | CIBA-GEIGY CORPORATION (US) | 1992-10-06 | — | — | US | disclosed |
| US-5108887-A | Zeromethine merocyanine dyes as J-aggregating spectral sensitizers for tabular emulsions | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-04-28 | — | — | US | disclosed |
| EP-0161220-B1 | PROCESS FOR THE PREPARATION OF BETA-(BENZOTHIAZOLYLTHIO) AND BETA (BENZIMIDAZOLYLTHIO)CARBOXYLIC-ACID DERIVATIVES | CIBA-GEIGY AG (CH) | 1991-08-14 | — | — | EP | disclosed |
| EP-0129506-B1 | HETEROCYCLICALLY SUBSTITUTED THIO(CYCLO)ALKANE POLYCARBOXYLIC ACIDS | CIBA-GEIGY AG (CH) | 1991-03-06 | — | — | EP | disclosed |
| US-4652653-A | Process for the preparation of β-(benzothiazolylthio)- and β-(benzimidazolylthio)-carboxylic acid derivatives | CIBA-GEIGY CORPORATION (US) | 1987-03-24 | — | — | US | disclosed |
| US-4612378-A | Process for the preparation of β-(benzothiazolylthio)- and β-(benzimidazolylthio-carboxylic acids | CIBA-GEIGY CORPORATION (US) | 1986-09-16 | — | — | US | disclosed |
| EP-0161220-A2 | Process for the preparation of beta-(benzothiazolylthio) and beta (benzimidazolylthio)carboxylic-acid derivatives | CIBA-GEIGY AG (CH) | 1985-11-13 | — | — | EP | disclosed |
| EP-0129506-A2 | Heterocyclically substituted thio(cyclo)alkane polycarboxylic acids | CIBA-GEIGY AG (CH) | 1984-12-27 | — | — | EP | disclosed |
| EP-0126030-A2 | Process for the preparation of beta-(benzothiazolylthio) and beta-(benzimidazolylthio) carboxylic acids | CIBA-GEIGY AG (CH) | 1984-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | HDAC1, HDAC2, HDAC3 | DYRK1A 2035/4885ILK 2181/4885EPHX2 3864/4885 |
| US-12600837-B2 | Rubber composition and crosslinked rubber molded product | RER1, RIF1, SHC1 | DYRK1A 2835/4885ILK 238/4885EPHX2 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.